Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective

<i>Background and Objectives:</i> The rapid growth of the number of advanced Parkinson’s disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa–carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusio...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Węgrzynek-Gallina, Tomasz Chmiela, Michał Borończyk, Aleksandra Buczek, Patrycja Hudzińska, Hubert Bigajski, Damian Waksmundzki, Justyna Gawryluk, Joanna Siuda
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/1/27
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832587993113690112
author Julia Węgrzynek-Gallina
Tomasz Chmiela
Michał Borończyk
Aleksandra Buczek
Patrycja Hudzińska
Hubert Bigajski
Damian Waksmundzki
Justyna Gawryluk
Joanna Siuda
author_facet Julia Węgrzynek-Gallina
Tomasz Chmiela
Michał Borończyk
Aleksandra Buczek
Patrycja Hudzińska
Hubert Bigajski
Damian Waksmundzki
Justyna Gawryluk
Joanna Siuda
author_sort Julia Węgrzynek-Gallina
collection DOAJ
description <i>Background and Objectives:</i> The rapid growth of the number of advanced Parkinson’s disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa–carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusion (CSAI). The objective of this study was to evaluate patients’ satisfaction and the factors influencing preferences for CSAI and LCIG. <i>Materials and Methods:</i> The research focused on individuals diagnosed with advanced PD undergoing DAT at the Neurology Department of the University Hospital in Katowice. A telephone survey conducted between June and July 2024 evaluated the experiences of patients with LCIG and CSAI. The Parkinson’s Disease Questionnaire (PDQ-8) and the Stress Scale for Family Caregivers (BSFC-s) were applied. Based on medical record data comprising reasons for the exclusion of individuals, disease-related and treatment data were collected. <i>Results:</i> Among the original cohort of 64 patients, 50 completed the survey, including 31 who might choose between infusion therapies. The average patient ages were 70.6 ± 4.7 (CSAI) and 71.2 ± 7.2 years (LCIG), with disease durations of 15 (IQR: 12–19) and 18 (IQR: 13–19) years, respectively. LCIG patients presented higher PDQ-8 scores (20 (IQR: 13–27) vs. 13 (IQR: 6–19), <i>p</i> = 0.008), and higher BSFC-s scores (19 (IQR: 12–21) vs. 9 (IQR: 2.5–13), <i>p</i> = 0.011). Furthermore, significant factors influencing patient preferences included fear of surgery (75% vs. 36.8%, <i>p</i> = 0.043) and concerns about DAT safety (83.3% vs. 47.4%, <i>p</i> = 0.049). <i>Conclusions:</i> LCIG and CSAI therapies offer benefits and disadvantages, with safety concerns and fear of surgery seeming to be decisive in the decision-making process.
format Article
id doaj-art-5bce610bdf3940128270821a239b492f
institution Kabale University
issn 1010-660X
1648-9144
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-5bce610bdf3940128270821a239b492f2025-01-24T13:40:18ZengMDPI AGMedicina1010-660X1648-91442024-12-016112710.3390/medicina61010027Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient PerspectiveJulia Węgrzynek-Gallina0Tomasz Chmiela1Michał Borończyk2Aleksandra Buczek3Patrycja Hudzińska4Hubert Bigajski5Damian Waksmundzki6Justyna Gawryluk7Joanna Siuda8Department of Neurology, Faculty of Medical Sciences in Katowice, University Clinical Centre Prof K. Gibinski, Medical University of Silesia, 14 Medykow St. 40-752 Katowice, PolandDepartment of Neurology, Faculty of Medical Sciences in Katowice, University Clinical Centre Prof K. Gibinski, Medical University of Silesia, 14 Medykow St. 40-752 Katowice, PolandDepartment of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, 45/47 Ziolowa St., 40-635 Katowice, PolandStudents’ Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 14 Medykow St, 40-752 Katowice, PolandStudents’ Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 14 Medykow St, 40-752 Katowice, PolandStudents’ Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 14 Medykow St, 40-752 Katowice, PolandStudents’ Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 14 Medykow St, 40-752 Katowice, PolandDepartment of Neurology, Faculty of Medical Sciences in Katowice, University Clinical Centre Prof K. Gibinski, Medical University of Silesia, 14 Medykow St. 40-752 Katowice, PolandDepartment of Neurology, Faculty of Medical Sciences in Katowice, University Clinical Centre Prof K. Gibinski, Medical University of Silesia, 14 Medykow St. 40-752 Katowice, Poland<i>Background and Objectives:</i> The rapid growth of the number of advanced Parkinson’s disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa–carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusion (CSAI). The objective of this study was to evaluate patients’ satisfaction and the factors influencing preferences for CSAI and LCIG. <i>Materials and Methods:</i> The research focused on individuals diagnosed with advanced PD undergoing DAT at the Neurology Department of the University Hospital in Katowice. A telephone survey conducted between June and July 2024 evaluated the experiences of patients with LCIG and CSAI. The Parkinson’s Disease Questionnaire (PDQ-8) and the Stress Scale for Family Caregivers (BSFC-s) were applied. Based on medical record data comprising reasons for the exclusion of individuals, disease-related and treatment data were collected. <i>Results:</i> Among the original cohort of 64 patients, 50 completed the survey, including 31 who might choose between infusion therapies. The average patient ages were 70.6 ± 4.7 (CSAI) and 71.2 ± 7.2 years (LCIG), with disease durations of 15 (IQR: 12–19) and 18 (IQR: 13–19) years, respectively. LCIG patients presented higher PDQ-8 scores (20 (IQR: 13–27) vs. 13 (IQR: 6–19), <i>p</i> = 0.008), and higher BSFC-s scores (19 (IQR: 12–21) vs. 9 (IQR: 2.5–13), <i>p</i> = 0.011). Furthermore, significant factors influencing patient preferences included fear of surgery (75% vs. 36.8%, <i>p</i> = 0.043) and concerns about DAT safety (83.3% vs. 47.4%, <i>p</i> = 0.049). <i>Conclusions:</i> LCIG and CSAI therapies offer benefits and disadvantages, with safety concerns and fear of surgery seeming to be decisive in the decision-making process.https://www.mdpi.com/1648-9144/61/1/27Parkinson’s diseaseinfusion therapieslevodopa–carbidopa intestinal gelcontinuous subcutaneous apomorphine infusionpatients’ preferences
spellingShingle Julia Węgrzynek-Gallina
Tomasz Chmiela
Michał Borończyk
Aleksandra Buczek
Patrycja Hudzińska
Hubert Bigajski
Damian Waksmundzki
Justyna Gawryluk
Joanna Siuda
Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
Medicina
Parkinson’s disease
infusion therapies
levodopa–carbidopa intestinal gel
continuous subcutaneous apomorphine infusion
patients’ preferences
title Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
title_full Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
title_fullStr Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
title_full_unstemmed Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
title_short Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
title_sort satisfaction and preferences for infusion therapies in advanced parkinson s disease patient perspective
topic Parkinson’s disease
infusion therapies
levodopa–carbidopa intestinal gel
continuous subcutaneous apomorphine infusion
patients’ preferences
url https://www.mdpi.com/1648-9144/61/1/27
work_keys_str_mv AT juliawegrzynekgallina satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT tomaszchmiela satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT michałboronczyk satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT aleksandrabuczek satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT patrycjahudzinska satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT hubertbigajski satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT damianwaksmundzki satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT justynagawryluk satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective
AT joannasiuda satisfactionandpreferencesforinfusiontherapiesinadvancedparkinsonsdiseasepatientperspective